Literature DB >> 27984110

More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.

J B Eifler1, J Alvarez2, T Koyama2, R M Conwill1, C R Ritch3, K E Hoffman4, M J Resnick1, D F Penson1, D A Barocas5.   

Abstract

PURPOSE: Urologists have been criticized for overtreating men with low risk prostate cancer and for passively observing older men with higher risk disease. Proponents of active surveillance for low risk disease and critics of watchful waiting for higher risk disease have advocated for more judicious use of observation. Thus, we compared 2 population based cohorts to determine how expectant management has evolved during the last 2 decades.
MATERIALS AND METHODS: A total of 5,871 men with localized prostate cancer were enrolled in the PCOS (Prostate Cancer Outcomes Study) or the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study. We compared the use of definitive treatment vs expectant management (watchful waiting or active surveillance) across cohorts, focusing on the influence of disease risk, age and comorbidities.
RESULTS: Use of watchful waiting or active surveillance was similar in PCOS and CEASAR (14% in each). Compared to the PCOS, more men in the CEASAR study with low risk disease selected watchful waiting or active surveillance (25% vs 15%, respectively), whereas fewer men with intermediate (7% vs 14%) and high risk (3% vs 10%) disease chose watchful waiting or active surveillance (p <0.001 for each). The association of disease risk with watchful waiting or active surveillance was significantly larger in CEASAR than in PCOS (OR 7.3, 95% CI 3.4 to 15.7). Older age was associated with watchful waiting or active surveillance in both cohorts but there was no association between comorbidity and watchful waiting or active surveillance in the CEASAR study.
CONCLUSIONS: Use of watchful waiting or active surveillance was more aligned with disease risk in CEASAR compared to PCOS, suggesting there has been a pivot from watchful waiting to active surveillance. While older men were more likely to be observed, comorbidity had little, if any, influence.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antineoplastic protocols; prostatic neoplasms; risk assessment; watchful waiting

Mesh:

Substances:

Year:  2016        PMID: 27984110      PMCID: PMC5315642          DOI: 10.1016/j.juro.2016.10.067

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

1.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

2.  Trends in the treatment of localized prostate cancer using supplemented cancer registry data.

Authors:  Ann S Hamilton; Peter C Albertsen; Terri Kang Johnson; Richard Hoffman; Donna Morrell; Dennis Deapen; David F Penson
Journal:  BJU Int       Date:  2010-08-24       Impact factor: 5.588

3.  Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram.

Authors:  A Kutikov; M R Cooperberg; A T Paciorek; R G Uzzo; P R Carroll; S A Boorjian
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-06-19       Impact factor: 5.554

4.  Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.

Authors:  Justin E Bekelman; Nandita Mitra; Elizabeth A Handorf; Robert G Uzzo; Stephen A Hahn; Daniel Polsky; Katrina Armstrong
Journal:  J Clin Oncol       Date:  2015-01-05       Impact factor: 44.544

5.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

6.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.

Authors:  Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

Review 8.  The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Mark S Litwin; Deborah P Lubeck; Shilpa S Mehta; James M Henning; Peter R Carroll
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

9.  Increasing use of observation among men at low risk for prostate cancer mortality.

Authors:  Chad R Ritch; Amy J Graves; Kirk A Keegan; Shenghua Ni; Jeffrey C Bassett; Sam S Chang; Matthew J Resnick; David F Penson; Daniel A Barocas
Journal:  J Urol       Date:  2014-09-06       Impact factor: 7.450

10.  Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.

Authors:  Timothy J Daskivich; Julie Lai; Andrew W Dick; Claude M Setodji; Janet M Hanley; Mark S Litwin; Christopher Saigal
Journal:  Urology       Date:  2016-04-11       Impact factor: 2.649

View more
  3 in total

1.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

2.  Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy.

Authors:  Jennifer B Gordetsky; Benjamin Saylor; Sejong Bae; Jeffrey W Nix; Soroush Rais-Bahrami
Journal:  Urol Oncol       Date:  2018-03-08       Impact factor: 2.954

Review 3.  Quality of care and economic considerations of active surveillance of men with prostate cancer.

Authors:  Christopher P Filson
Journal:  Transl Androl Urol       Date:  2018-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.